Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

$Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010$

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma, a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European Hematology Association meeting being held June 10-13, 2010 in Barcelona, Spain.

11 Jun 2010

Phase II study results of riociguat for CTEPH and PAH published online

Bayer HealthCare Pharmaceuticals, Inc. today announced that the study "Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study" was published online this week by the European Respiratory Journal. Results of this study to assess the safety, tolerability and the feasibility of individual dose titration of riociguat were previously presented at the 2009 International Conference of the American Thoracic Society.

11 Jun 2010

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Data from the RE-NOVATE® II study presented today at the 15th Annual Congress of the European Hematology Association (EHA) have shown that dabigatran etexilate 220mg once daily is as effective and safe as enoxaparin 40mg in preventing venous thromboembolism (VTE) after total hip replacement surgery.

11 Jun 2010

Telomere length can act as stopwatch to predict progression of leukaemia: Research

Scientists have pinpointed key changes to the telomeres in the cells of leukaemia patients which could play a crucial role in the earliest stages of the disease, according to research published online in the journal Blood.

11 Jun 2010

$Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL$

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Cell Therapeutics, Inc. today reported exploratory analyses of the data at study completion from the Company's pivotal PIX301 trial of Pixuvri, the first randomized controlled trial in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma.

11 Jun 2010

UAB researchers win grant to study metastasis of dead cancer cells

Researchers with the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center and UAB Department of Chemistry have won an $805,000 grant from the U.S. Department of Defense Breast Cancer Research Program to study whether dead cancer cells left over after treatment encourage cancer's spread to other parts of the body.

11 Jun 2010

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

Genzyme Corporation and Carl C. Icahn and certain of his affiliated private investment funds announced today an agreement to settle their proxy contest.

10 Jun 2010

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO Pte Ltd today announced that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the U.S. and Australia for the treatment of myelofibrosis (MF).

9 Jun 2010

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced four-year follow-up results from a Phase 3 randomized, open-label, dose-optimization study of SPRYCEL® (dasatinib) in chronic-phase chronic myeloid leukemia (CML-CP) patients resistant or intolerant to Gleevec®* (imatinib mesylate). At four years, for all patients administered SPRYCEL 100 mg once daily, overall survival was 82% (95% CI: 76%-88%) and progression-free survival was 66% (95% CI: 57%-74%).

9 Jun 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Genetic mutations help predict risk of prostate cancer in younger men: Researchers

Prostate cancer has become more common in younger men, and it's often more aggressive in these men. A new study from researchers at the University of Michigan Comprehensive Cancer Center has found that a series of genetic mutations could help detect this early onset prostate cancer.

8 Jun 2010

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

8 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Array BioPharma Inc. today announced the presentation of positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma.

7 Jun 2010

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, both in Detroit, and the Children's Hospital of Michigan/Detroit Medical Center, presented preliminary data that identified a potential link between Gilbert's Syndrome and the development of a specific subtype of childhood acute lymphoblastic leukemia (ALL). The findings were announced today at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Grifols to acquire Talecris Biotherapeutics

Grifols a global healthcare company and leading producer of plasma protein therapies, and Talecris a U.S.-based biotherapeutics products company, today announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares having an aggregate value today of approximately $3.4 billion (euro 2.8 billion), creating a global leader of life-saving and life enhancing plasma protein therapeutics.

7 Jun 2010

ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer.

7 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Hematology News and Research

Further Reading

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Phase II study results of riociguat for CTEPH and PAH published online

Dabigatran Etexilate anticoagulant as effective as Enoxaparin in preventing venous thromboembolism

Telomere length can act as stopwatch to predict progression of leukaemia: Research

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

UAB researchers win grant to study metastasis of dead cancer cells

Genzyme, Carl C. Icahn announce agreement to settle proxy contest

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Genetic mutations help predict risk of prostate cancer in younger men: Researchers

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

Grifols to acquire Talecris Biotherapeutics

ArQule, Daiichi Sankyo present positive data from Phase 2 combination ARQ 197 trial for lung cancer at ASCO

New clinical research findings on oncology to be highlighted at ASCO 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News